Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody

Expert Opinion on Drug Delivery

Volumn 12, Issue 2, 2015, Pages 207-222

  Pardridge, William M ^a  

^a ArmaGen Technologies Inc   (United States)

Author keywords

Biologic drugs; Blood brain barrier; Fusion proteins; Monoclonal antibody; Transferrin receptor

Indexed keywords

AVIDIN; BISPECIFIC ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G FUSION PROTEIN; IRON; LYSOSOME ENZYME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRANSFERRIN RECEPTOR FUSION PROTEIN; NEUROTROPHIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; PEPTIDE; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; ANTIBODY ENGINEERING; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CEREBROVASCULAR ACCIDENT; CHRONIC DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG UPTAKE; ENDOCYTOSIS; GENETIC ENGINEERING; HUMAN; LYSOSOME STORAGE DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; REVIEW; TRANSCYTOSIS; ANIMAL; BRAIN; IMMUNOLOGY; METABOLISM; MOUSE; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTIBODIES, MONOCLONAL; AVIDIN; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN G; MICE; PEPTIDES; RADIOPHARMACEUTICALS; RECEPTORS, TRANSFERRIN;

EID: 84921443725     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.952627     Document Type: Review

References (85)

1. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32(11):1959-72
2. Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012;503:269-92
3. Cheng Y, Zak O, Aisen P, et al. Structure of the human transferrin receptor-transferrin complex. Cell 2004;116(4):565-76
4. Kawabata H, Yang R, Hirama T, et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999;274(30):20826-32
5. Wallace DF, Summerville L, Lusby PE, Subramaniam VN. First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut 2005;54(7):980-6
6. Fleming RE, Migas MC, Holden CC, et al. Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc Natl Acad Sci USA 2000;97(5):2214-19
7. Lai A, Sisodia SS, Trowbridge IS. Characterization of sorting signals in the beta-amyloid precursor protein cytoplasmic domain. J Biol Chem 1995;270(8):3565-73
8. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier transferrin receptor. Metabolism 1987;36(9):892-5
9. Li JY, Boado RJ, Pardridge WM. Blood-brain barrier genomics. J Cereb Blood Flow Metab 2001;21(1):61-8
10. Jefferies WA, Brandon MR, Hunt SV, et al. Transferrin receptor on endothelium of brain capillaries. Nature 1984;312(5990):162-3
11. Pardridge WM, Buciak JL, Friden PM. Selective transport of an anti-transferrin receptor antibody through the bloodbrain barrier in vivo. J Pharmacol Exp Ther 1991;259(1):66-70
12. Lesley J, Hyman R, Schulte R, Trotter J. Expression of transferrin receptor on murine hematopoietic progenitors. Cell Immunol 1984;83(1):14-25
13. Kissel K, Hamm S, Schulz M, et al. Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. Histochem Cell Biol 1998;110(1):63-72
14. Lee HJ, Engelhardt B, Lesley J, et al. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther 2000;292(3):1048-52
15. White S, Taetle R, Seligman PA, et al. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res 1990;50(19):6295-301
16. Friden PM, Olson TS, Obar R, et al. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor. J Pharmacol Exp Ther 1996;278(3):1491-8
17. Taylor EM, Crowe A, Morgan EH. Transferrin and iron uptake by the brain: effects of altered iron status. J Neurochem 1991;57(5):1584-92
18. Roberts RL, Fine RE, Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J Cell Sci 1993;104(Pt 2):521-32
19. Zhang Y, Pardridge WM. Rapid transferrin efflux from brain to blood across the blood-brain barrier. J Neurochem 2001;76(5):1597-600
20. Okamura T, Igarashi J, Kikuchi T, et al. A radiotracer method to study efflux transport of iodide liberated from thyroid hormones via deiodination metabolism in the brain. Life Sci 2009;84(23-24):791-5
21. Vorbrodt AW. Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J Neurocytol 1989;18(3):359-68
22. Huwyler J, Pardridge WM. Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J Neurochem 1998;70(2):883-6
23. Fishman JB, Rubin JB, Handrahan JV, et al. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 1987;18(2):299-304
24. Skarlatos S, Yoshikawa T, Pardridge WM. Transport of [125I] transferrin through the rat blood-brain barrier. Brain Res 1995;683(2):164-71
25. Duffy KR, Pardridge WM. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 1987;420(1):32-8
26. Bickel U, Kang YS, Yoshikawa T, Pardridge WM. In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem 1994;42(11):1493-7
27. Gjedde A, Christensen O. Estimates of Michaelis-Menten constants for the two membranes of the brain endothelium. J Cereb Blood Flow Metab 1984;4(2):241-9
28. Pardridge WM. Brain drug targeting. CUP, Cambridge; 2001
29. Fillebeen C, Descamps L, Dehouck MP, et al. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem 1999;274(11):7011-17
30. Pardridge WM, Triguero D, Yang J, Cancilla PA. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J Pharmacol Exp Ther 1990;253(2):884-91
31. Ji B, Maeda J, Higuchi M, et al. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 2006;78(8):851-5
32. Demeule M, Poirier J, Jodoin J, et al. High transcytosis of melanotransferrin (p97) across the blood-brain barrier. J Neurochem 2002;83(4):924-33
33. Pan W, Kastin AJ, Zankel TC, et al. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J Cell Sci 2004;117(Pt 21):5071-8
34. Richardson DR, Morgan EH. The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. Biochim Biophys Acta 2004;1690(2):124-33
35. McGrath JP, Cao X, Schutz A, et al. Bifunctional fusion between nerve growth factor and a transferrin receptor antibody. J Neurosci Res 1997;47(2):123-33
36. Boado RJ, Pardridge WM. Genetic engineering of IgG-glucuronidase fusion proteins. J Drug Target 2010;18(3):205-11
37. Zhou QH, Boado RJ, Lu JZ, et al. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metab Dispos 2010;38(4):566-72
38. Zhou QH, Boado RJ, Lu JZ, et al. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. Mol Pharm 2010;7(6):2148-55
39. Zhou QH, Boado RJ, Hui EK, et al. Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab Dispos 2011;39(1):71-6
40. Boado RJ, Hui EK, Lu JZ, et al. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous trojan horse-iduronidase fusion protein. Mol Pharm 2011;8(4):1342-50
41. Zhou QH, Boado RJ, Lu JZ, et al. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse. Drug Metab Dispos 2012;40(2):329-35
42. Boado RJ, Zhou QH, Lu JZ, et al. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm 2010;7(1):237-44
43. Fu A, Zhou QH, Hui EK, et al. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res 2010;1352:208-13
44. Zhou QH, Hui EK, Lu JZ, et al. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse. Brain Res 2011;1382:315-20
45. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol 2008;36(12):1573-84
46. Zhou QH, Sumbria R, Hui EK, et al. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J Pharmacol Exp Ther 2011;339(2):618-23
47. Boado RJ, Hui EK, Lu JZ, et al. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J Biotechnol 2010;146(1-2):84-91
48. Sumbria RK, Boado RJ, Pardridge WM. Brain protection from stroke with intravenous TNF-alpha decoy receptortrojan horse fusion protein. J Cereb Blood Flow Metab 2012;32(10):1933-8
49. Sumbria RK, Boado RJ, Pardridge WM. Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins. Brain Res 2013;1507:91-6
50. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283(12):1571-7
51. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370(4):322-33
52. Boado RJ, Zhang Y, Zhang Y, et al. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem 2007;18(2):447-55
53. Schlageter NL, Carson RE, Rapoport SI. Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography. J Cereb Blood Flow Metab 1987;7(1):1-8
54. Seubert P, Barbour R, Khan K, et al. Antibody capture of soluble Abeta does not reduce cortical abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008;5(2):65-71
55. Sumbria RK, Hui EK, Lu JZ, et al. Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. Mol Pharm 2013;10(9):3507-13
56. Wilcock DM, Alamed J, Gottschall PE, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 2006;26(20):5340-6
57. Jancso G, Domoki F, Santha P, et al. Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci Lett 1998;253(2):139-41
58. Su GC, Arendash GW, Kalaria RN, et al. Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res 1999;818(1):105-17
59. Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24(2):198-203
60. Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 2002;81(1):203-6
61. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 2001;114(1-2):168-72
62. Cheng SH, Smith AE. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 2003;10(16):1275-81
63. Boado RJ, Hui EK, Lu JZ, et al. Blood-brain barrier molecular Trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem 2013;24(10):1741-9
64. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167(3):267-77
65. Scott HS, Anson DS, Orsborn AM, et al. Human alpha-L-iduronidase: cDNA isolation and expression. Proc Natl Acad Sci USA 1991;88(21):9695-9
66. Wilson PJ, Morris CP, Anson DS, et al. Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci USA 1990;87(21):8531-5
67. Green NM. Avidin. Adv Protein Chem 1975;29:85-133
68. Yoshikawa T, Pardridge WM. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J Pharmacol Exp Ther 1992;263(2):897-903
69. Saito Y, Buciak J, Yang J, Pardridge WM. Vector-mediated delivery of 125I-labeled beta-amyloid peptide Abeta1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the Abeta1-40/vector complex. Proc Natl Acad Sci USA 1995;92(22):10227-31
70. Pardridge WM, Boado RJ, Kang YS. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci USA 1995;92(12):5592-6
71. Shin SU, Wu D, Ramanathan R, et al. Functional and pharmacokinetic properties of antibody-avidin fusion proteins. J Immunol 1997;158(10):4797-804
72. Boado RJ, Zhang Y, Zhang Y, et al. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug Chem 2008;19(3):731-9
73. Zhou QH, Lu JZ, Hui EK, et al. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. Bioconjug Chem 2011;22(8):1611-18
74. Ono M, Cheng Y, Kimura H, et al. Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of beta-amyloid plaques in Alzheimer's brains. J Med Chem 2011;54(8):2971-9
75. Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011;3(84):84ra44
76. Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 2012;28(1):49-69
77. Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014;81(1):49-60
78. Lesley J, Schulte R, Woods J. Modulation of transferrin receptor expression and function by antitransferrin receptor antibodies and antibody fragments. Exp Cell Res 1989;182(1):215-33
79. Atwal JK, Chen Y, Chiu C, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 2011;3(84):84ra43
80. Zhou QH, Boado RJ, Hui EK, et al. Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein. Drug Metab Dispos 2011;39(7):1149-54
81. Couch JA, Yu YJ, Zhang Y, et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med 2013;5(183):183ra157; 181-112
82. Boado RJ, Hui EK, Lu JZ, Pardridge WM. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. Bioconjug Chem 2013;24(1):97-104
83. Boado RJ, Hui EK, Lu JZ, Pardridge WM. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in rhesus monkeys. Biotechnol Bioeng 2014. [Epub ahead of print]
84. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor. J Neurochem 1985;44(6):1771-8
85. Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011;117(2):333-45